Dyne Therapeutics has appointed Barry Greene to its Board of Directors as the company prepares for a planned transition into a commercial biotechnology company. The appointment, effective June 22, 2026, aims to strengthen the board ahead of potential product launches and revenue generation. Greene brings more than three decades of experience in the biopharmaceutical industry, with a track record of building and scaling innovative companies across rare diseases, neuroscience, and oncology.

Board Strengthening for Commercial Phase

Jason Rhodes, chairman of Dyne’s Board of Directors and partner at Atlas Venture, emphasized the strategic timing of the appointment. "Dyne is approaching a planned transformation into a commercial biotechnology company. In anticipation of potential product launches and revenue generation, we are expanding and strengthening the Board as we partner with John and the management team," said Rhodes. The move is designed to maximize patient and shareholder value as the company advances its clinical programs.

Barry Greene’s Industry Experience

Greene’s extensive background includes serving as chief executive officer of Sage Therapeutics from December 2020 to July 2025, where he led the company’s focus on brain health disorders and the launch of a novel treatment for postpartum depression. Prior to Sage, he spent nearly two decades at Alnylam Pharmaceuticals, including as president and chief operating officer, helping build the company into a fully integrated, multi-product biopharmaceutical organization. Earlier in his career, he served as general manager of oncology at Millennium Pharmaceuticals, leading the approval and launch of VELCADE® (bortezomib).

Current Roles and Educational Background

Greene currently serves as lead independent director of Karyopharm Therapeutics, a position he has held since 2013. He has also served on the boards of Sage Therapeutics and Acorda Therapeutics. Greene holds a Bachelor of Science degree in industrial engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University’s Medical School and Fuqua School of Business.

Dyne’s Clinical and Regulatory Momentum

John Cox, president and chief executive officer of Dyne Therapeutics, highlighted Greene’s ability to translate innovation into a scalable business. "Barry understands what it takes to translate innovation into a scalable, high-performing biotechnology business," said Cox. Dyne is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease, and multiple DMD mutations.

Dyne Therapeutics, Inc. granted inducement equity awards to 6 newly hired employees as a material inducement for their acceptance of employment. The awards were issued in accordance with Nasdaq Listing Rule 5635(c)(4). The grants included non-statutory stock options to purchase an aggregate of 126,000 shares of common stock and restricted stock units covering 40,100 shares.

The stock options have a ten-year term and an exercise price equal to the closing price of Dyne's common stock on The Nasdaq Global Select Market on June 16, 2026. Vesting for the options occurs over four years, with 25% vesting on the first anniversary of the employee's start date and the remainder vesting in 12 equal quarterly installments, subject to continued service.

The restricted stock units are scheduled to vest over four years from the applicable employee's start date in four equal annual installments, also subject to continued service. These awards are governed by the terms of the award agreements and Dyne's 2024 Inducement Stock Incentive Plan.

Breakdown of Inducement Awards